12 completed, 3 unknown, 1 terminated, 1 withdrawn. 4 Phase 2, 4 Phase 4, 3 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 4 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Not applicable | 2 | Terminated 1, Withdrawn 1 |
Follow Thiazolidinediones: new trials by email Literature Review of Thiazolidinediones trials Research Report on Thiazolidinediones
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Omarigliptin, Sulphonylureas, Metformin - Type2diabetes | Phase 4 | Unknown | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 938 | 2024-09-01 | 2024-07-16 |
| Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg - Impaired Glucose Tolerance, Insulin Sensitivity | Phase 2 | Unknown | Oslo University Hospital | 64 | 2021-02-10 | 2021-04-08 |
| Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus Liraglutide, Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides - Type 2 Diabetes Mellitus | Phase 3 | Completed | Third Military Medical University | 30 | 2021-01-20 | 2022-05-04 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial Diabetes Medicines, Dapagliflozin - Type 2 Diabetes Mellitus | Phase 4 | Completed | Mackay Memorial Hospital | 76 | 2019-04-01 | 2023-03-22 |
| A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease Canagliflozin, Empagliflozin, Dapagliflozin - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Completed | Janssen Research & Development, LLC | 714582 | 2018-02-22 | 2025-06-25 | |
| A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey INSULIN GLARGINE (U300), metformin, sulfonylurea - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 112 | 2016-11-30 | 2019-01-14 |
| Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors - Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Novo Nordisk A/S | 1991 | 2016-03-28 | 2020-07-07 |
| Incretin-based Drugs and the Risk of Heart Failure DPP-4 inhibitors, GLP-1 analogs, Insulins - Type 2 Diabetes Mellitus | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1499650 | 2014-03-01 | 2016-04-19 | |
| Incretin-based Drugs and Acute Pancreatitis DPP-4 inhibitors, GLP-1 analogs, Insulins - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 1417914 | 2014-03-01 | 2016-11-03 | |
| Incretin-based Drugs and Pancreatic Cancer DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas - Diabetes Mellitus, Type 2 | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 886172 | 2014-03-01 | 2016-03-14 | |
| PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes second- or third-line glucose-lowering diabetes treatment - Diabetes | Completed | Royal Devon and Exeter NHS Foundation Trust | 820 | 2013-03-01 | 2018-06-21 | |
| Proteus Sustained Behavior Change Study Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) - Type 2 Diabetes Mellitus | Not applicable | Withdrawn | Proteus Digital Health, Inc. | 2012-02-01 | 2013-03-05 | |
| Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease Life style intervention, pioglitazone, berberine - Nonalcoholic Fatty Liver Disease | Phase 2 | Completed | Xin Gao | 184 | 2008-03-01 | 2012-06-05 |
| Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease exercise training, exercise training + metformin, exercise training + glitazone - Severe Coronary Artery Disease, Obesity | Not applicable | Terminated | University of Leipzig | 29 | 2007-07-01 | 2020-11-27 |
| Rosiglitazone Effect on Mitochondria and Lipoatrophy Rosiglitazone, Placebo - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 71 | 2006-07-01 | 2017-02-06 |
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Coronary Artery Bypass, Biguanides, thiazolidinediones - Coronary Disease, Cardiovascular Diseases | Phase 3 | Completed | University of Pittsburgh | 2368 | 2000-09-01 | 2016-02-08 |
Diabetes Mellitus, Type 2 (12) · Diabetes Mellitus (3) · Cardiovascular Diseases (2) · Glucose Intolerance (2) · Insulin Resistance (2) · Cognitive Dysfunction (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Dementia, Vascular (1) · Glucose Metabolism Disorders (1) · HIV Infections (1) · Heart Diseases (1) · Heart Failure (1) · Ischemic Stroke (1) · Lipodystrophy (1)
Canadian Network for Observational Drug Effect Studies, CNODES (3) · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (1) · Jaime Daniel Mondragon (1) · Janssen Research & Development, LLC (1) · Mackay Memorial Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novo Nordisk A/S (1) · Oslo University Hospital (1) · Proteus Digital Health, Inc. (1) · Royal Devon and Exeter NHS Foundation Trust (1) · Sanofi (1) · Third Military Medical University (1) · University of Leipzig (1) · University of Pittsburgh (1) · Xin Gao (1)
Canada (4) · United States (4) · China (2) · Turkey (Türkiye) (2) · Bangladesh (1) · Colombia (1) · Germany (1) · India (1) · Latvia (1) · Lebanon (1) · Mexico (1) · Norway (1) · Puerto Rico (1) · Russia (1) · Serbia (1)
Pierre Ernst, MD, MSc (3) · Andrew T Hattersley, FRCP, DM, BM (1) · Bernard Chaitman, MD (1) · Bonnie Spring, PhD (1) · Burton Sobel (1) · Faria Afsana, MD (1) · Gerhard Schuler, Prof. of Medicine (1) · Grace McComsey (1) · Kamal Jethwani, MD (1)
PMID 20204386, PMID 20453626, PMID 20969457, PMID 21444887, PMID 21473976, PMID 21742107, PMID 21768545, PMID 21835316, PMID 21911782, PMID 22496082, PMID 23008442, PMID 23040716, PMID 23410541, PMID 23500245, PMID 23500281, PMID 23735723, PMID 23757426, PMID 23857320, PMID 23910429, PMID 24178969, PMID 26252777, PMID 26267622, PMID 26271057, PMID 26853953, PMID 26888382, PMID 27007958, PMID 27289411, PMID 27479930, PMID 27629750, PMID 28095900, PMID 28126156, PMID 28903941, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29573529, PMID 30286920, PMID 31236801, PMID 31248555, PMID 31535829, PMID 31590967, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307
2015 (1), U01HL061744 (1), U01HL061746 (1), U01HL061748 (1), U01HL063804 (1)